Competitive Positioning

Honest intel for rep conversations · Updated Q1 2026

Section A — Competitor Comparison

Green = IS advantage · Amber = neutral or context-dependent · Red = genuine competitor strength

Category	da Vinci Xi Intuitive Surgical	da Vinci 5 Intuitive Surgical	Hugo RAS Medtronic	Versius Plus CMR Surgical	Ottava Johnson & Johnson · Coming
Capital Cost Range	$1.5M – $2.5M	$2.0M – $2.5M	$0.9M – $1.5M ✓ Lower capital	$0.75M – $1.0M ✓ Cheapest	Unknown
Instrument Cost / Case	$1,500 – $3,500	$1,500 – $3,500	~$1,000 ✓ Lower per-case	~$800 – $1,000 ✓ Lowest	Unknown
Procedure Breadth (US FDA-cleared)	Full breadth — all specialties ✅	Full breadth + expanding ✅	Urology only ⚠️ Cleared Dec 2025 (US)	Cholecystectomy only ❌ Cleared Dec 2025 (US)	None yet ❌ FDA De Novo Jan 2026
Force / Haptic Feedback	No ❌	Yes ✅ 43% tissue force reduction	No ❌	No ❌	Unknown
AI / Data Platform	Moderate AI	Advanced AI ✅ 10,000× compute · Case video · Skill benchmarking · Coaching	Touch Surgery ⚠️ Post-op AI, remote proctoring — solid	Limited ❌	Unknown
Surgeon Console Type	Immersive closed console ✅	Immersive + force feedback ✅	Open console ⚠️ Competitor strength for ambient training visibility	Compact open	Unknown
Portability / Modular Arms	Low portability	Low portability	High ✓ Modular arms, multi-room capable	Highest ✓ Stackable — most portable	Unknown
Installed Base (US)	9,000+ ✅	~300 (YE 2024) — growing ✅	~42 EU · Minimal US ❌	Minimal ❌	None ❌
US Market Readiness	Fully ready ✅	Fully ready ✅	Urology only ⚠️	Launching 2026 ❌	Expected late 2026–2027 ❌
Training Ecosystem	Best-in-class ✅	Best-in-class + AI coaching ✅	Building ❌	Limited ❌	None ❌
IS Recommended Config to compete at each price tier	vs Versius — Entry Tier PSC Basic · VSC Basic · SSC Basic Score 3.0 · Price: — Full IS breadth · All specialties · Matches Versius price point vs Hugo — Mid Tier PSC Upgraded · VSC Basic · SSC Basic Score 4.0 · Price: — Broader procedure mix than Hugo · Competes on capital · Full breadth advantage vs Hugo — Value Tier PSC Upgraded · VSC Upgraded · SSC Basic Score 4.75 · Price: — Enhanced imaging + AI viz · Still within Hugo's capital range · Clear value win		Competitor Gap Hugo: Urology only — even at Entry tier, IS covers GYN, colorectal, thoracic, bariatric Versius: Cholecystectomy only — IS Entry config at same price = full portfolio Ottava: No US clearance — not a real comparison yet

⚠️ Competitor strengths are flagged honestly — reps need accurate intel, not a filtered view. · IS config prices calculated from current component base price.

Section B — IS Competitive Moat

Why IS wins despite a higher price point

🏥

Procedure Breadth Lock-In

Hugo and Versius have 1–2 US-cleared indications. IS covers every specialty. A hospital choosing Hugo for prostatectomy still needs IS for GYN, colorectal, and thoracic — meaning two systems or accepted capability gaps.

🎓

Surgeon Training Network

IS's credentialing infrastructure creates real switching costs. Surgeons credentialed on IS aren't credentialed on Hugo. Retraining means downtime, case slowdowns, and credentialing delays that cost $30K+/week per physician.

🌐

Installed Base Network Effects

OR teams, scrub techs, and anesthesiologists know IS. 11,000+ systems globally. The familiarity of your entire OR staff is a tangible daily operational advantage.

🔒

Recurring Revenue Lock-In

IS instruments only work on IS systems — and that's a quality guarantee, not a trap. Every instrument is precision-built and tested for your exact system configuration.

📊

Unmatched Data Advantage

The da Vinci 5's AI runs on the world's largest robotic surgery dataset — 2.7M+ procedures in 2024 alone. No competitor can replicate this. Insight quality compounds with every case.

Section C — Objection Handler

Tap any objection to reveal the counter

Counter: True on capital. But Hugo is urology-only in the US. If your program does anything else robotically, you're still buying IS alongside it. On a total portfolio basis, the cost gap narrows fast — and IS's AMP model removes the upfront capital barrier entirely.

Counter: Versius requires ~208 cases/year just to break even — higher than IS or Hugo. Its US clearance covers cholecystectomy only as of 2026. For most programs, that's a very expensive single-procedure robot.

Counter: IS's credentialing and sim infrastructure is the industry gold standard. The open console aids ambient awareness — fair. But the dV5 adds force feedback and real-time AI coaching that no open console can replicate. Training quality isn't just about who can see the surgeon.

Counter: J&J submitted to FDA in January 2026. Realistic clearance is late 2026 at earliest — more likely 2027. That's 12–18 months of delayed program volume, lost surgeon recruitment, and procedure revenue left on the table. What does waiting cost your program?

Counter: IS's extended-use program reduces per-case instrument costs by 9–24%. At 300 cases/year, that's $150K–$300K+ in annual savings. And IS is the only system with force feedback — tissue force reduction of up to 43% has its own implications for complication rates and length of stay.

Counter: IS's AMP program bundles system, service, and financing into a single per-procedure operational fee. No capital line item, no downtime risk, fully operational budget treatment. Let me model what AMP looks like at your volume.

IS Competitive Intelligence · Internal use only · Data current as of Q1 2026